Alnylam Pharmaceuticals Submits New Drug Application for Experimental Acute Hepatic Porphyria Drug
Aymanjed / Pixabay

Alnylam Pharmaceuticals Submits New Drug Application for Experimental Acute Hepatic Porphyria Drug

According to a press release from Alnylam Pharmaceuticals, the Massachusetts-based biopharmaceutical company has completed the submission of its New Drug Application (NDA) for givosiran — its experimental acute hepatic porphyria…

Continue Reading Alnylam Pharmaceuticals Submits New Drug Application for Experimental Acute Hepatic Porphyria Drug
Better Than A Trip to Disney World? January 2018 Symposium in Orlando Focuses on Porphyrias
BBarth / Pixabay

Better Than A Trip to Disney World? January 2018 Symposium in Orlando Focuses on Porphyrias

On January 12-14, 2018 leading minds from around the world will convene in Orlando, Florida for the annual Heme Biosynthesis and the Porphyrias Recent Advances Conference. Yes, it's a mouthful,…

Continue Reading Better Than A Trip to Disney World? January 2018 Symposium in Orlando Focuses on Porphyrias